Short term oral minocycline treatment of meibomianitis.
OBJECTIVE
To evaluate the clinical impact, aqueous tear parameters, and meibomian gland morphology in patients with primary meibomianitis before, during, and 3 months after a course of oral minocycline.


METHODS
16 patients were prospectively enrolled, 11 male and five female (mean age 69 years old). Each patient received routine clinical evaluations before, after 3 months therapy, and at 6 month study follow up visit. The clinical appearance, tear volume, flow and turnover, evaporation, Schirmer I test, meibomian gland dropout, lissamine green staining, and bacteriology wer evaluated.


RESULTS
Improvement was observed in clinical signs of meibomianitis at the second and third visits. Microbial culture findings improved. Decreased aqueous tear volume and flow, and increased evaporation rate range at 35-45% relative humidity (RH) (p < 0.05) were also detected. Other related tear parameters did not change. Meibomian gland dropout showed no improvement.


CONCLUSIONS
3 months of oral minocycline resulted in clinical improvements in all meibomianitis signs that persisted for at least 3 months after discontinuation despite decreased aqueous tear volume and flow with increased evaporation (35-45% RH). However, there was improvement in the turbidity of secretions. Short term minocycline therapy probably has efficacy in the management of meibomianitis that extends beyond eradication of bacteria.
Aronowicz
J D
JD
Department of Opthalmology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9057, USA.
Shine
W E
WE
Oral
D
D
Vargas
J M
JM
McCulley
J P
JP
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001421:Bacteria, Anaerobic; D003228:Conjunctiva / Q000382:microbiology; D015352:Dry Eye Syndromes / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D005141:Eyelid Diseases / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008537:Meibomian Glands / Q000382:microbiology* / Q000473:pathology; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage* / Q000627:therapeutic use; D011446:Prospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus; D013212:Staphylococcus epidermidis; D013666:Tears / Q000502:physiology
D000900:Anti-Bacterial Agents; D008911:Minocycline